The VXM01-avelumab combination therapy was generally well-tolerated, with the majority of safety events being mild to moderate in severity. These safety and tolerability data are in-line with ...

"The completion of this Phase 2a study is a significant milestone for Vaximm AG, as it provides strong evidence that VXM01, in combination with avelumab is generally well-tolerated in patients ...

Results from Phase 2a Trial demonstrate a good safety and tolerability profile of VXM01 and Avelumab Combination Therapy in Glioblastoma, supporting further investigation of VXM01 The reported ...

The following is a summary of “FcγR3A polymorphism influences natural killer cell activation and response to anti-PD-L1 (avelumab) in gestational trophoblastic neoplasia,” published in the April 2025 ...

Among patients with recurrent glioblastoma (GBM), the combination of VXM01, an investigational oral anti–VEGFR-2 vaccine, and the PD-L1 inhibitor avelumab (Bavencio) was generally well tolerated, with ...

Results from Phase 2a Trial demonstrate a good safety and tolerability profile of VXM01 and Avelumab Combination Therapy in Glioblastoma, supporting further investigation of VXM01 BASEL, Switzerland I ...

“The completion of this Phase 2a study is a significant milestone for Vaximm AG, as it provides strong evidence that VXM01, in combination with avelumab is generally well-tolerated in patients with ...

According to the study design, no regular maintenance treatment with avelumab was planned in the comparator arm for patients who were progression-free following chemotherapy. However, maintenance ...

Real-World Data Back First-Line Avelumab and Axitinib in Advanced RCC ...